Resverlogix is sponsoring a symposium on June 5th at ERA-EDTA in Madrid entitled "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?". Three members of the Resverlogix Clinical Advisory Board are presenting at this symposium and from the sounds of it they will be talking up Resverlogix and Apabetalone. The other two presenters are renal clinicials from Madrid.

Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?

JUNE 5, 2017 - CME SYMPOSIUM AT ERA-EDTA 2017, MADRID, SPAIN

Introduction

The aim of this educational programme is to provide a balanced overview on a novel approach to reduce residual CV risk in patients with increase cardiovascular and renal risk, namely BET inhibition. BET refers to a bromodomain and extra-terminal domain of regulatory proteins. Its inhibition modifies gene expression via epigenetic mechanisms.

Date and venue

Symposium to be held during the 54th ERA EDTA Congress in Madrid, Spain

June 5, 2017 - 14.45 - 14.45 hrs

Educational objectives

• To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
• To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
• To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
• To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management

Agenda

Co-chairman:

Carmine Zoccali, MD CNR-IFC, Reggio Cal, Italy

Vincent M Brandenburg, MD Aachen, Germany

Topics

Introduction - Vincent M Brandenburg, MD, Aachen, Germany

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk? - Luis M Ruilope, MD, Hospital 12 de Octubre Madrid, Spain

Epigenetics as a novel strategy in cardiovascular and renal risk reduction: A closer look at BET as pathway for inhibition - Marta Ruiz-Ortega, Fundación Jiménez Díaz,Madrid, Spain

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap? - Kamyar Kalantar-Zade, MD, UC Irvine School of Medicine, Irvine, Ca, USA

Discussion & summary - Carmine Zoccali, MD, Reggio Cal, Italy

CME accreditation

CME accredition is applied for by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit

Funding

 The symposium is supported by an unrestricted educational grant from Resverlogix Corp